S104 Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate versus dual therapies in moderate-to-very severe COPD in the United Kingdom: analysis based on the KRONOS study

Autor:	N. Brighton, A. Walker, Ulf Holmgren, John Haughney, E. De Nigris, C. Treharne
Rok vydání:	2021
Předmět:	Budesonide medicine.medical_specialty Cost effectiveness business.industry Internal medicine medicine Formoterol Fumarate Severe copd business medicine.drug
Zdroj:	Ease that wheeze: managing risk in COPD.
DOI:	10.1136/thorax-2021-btsabstracts.110
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::109069a48d4d1d413335b760813d5637 https://doi.org/10.1136/thorax-2021-btsabstracts.110 Zobrazit plný text záznamu